EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study (Q62127975)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author

Ramon Andrade de Mello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ana Peixoto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Catarina Santos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Carla Pinto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Venceslau Hespanhol

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Manuel R. Teixeira

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

Antonió Manuel Ferreira Araújo

9 February 2020

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Filipa Soares Pires

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Dânia Sofia Marques

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Júlio Oliveira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ana Rodrigues

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Marta Soares

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Isabel Azevedo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Teresina Amaro

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Henrique Queiroga

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

29 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

2061-2068

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22843317%20AND%20SRC:MED&resulttype=core&format=json

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

9 February 2020

cites work

1 reference

12 December 2020

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

1 reference

12 December 2020

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

1 reference

12 December 2020

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

1 reference

12 December 2020

Frequency of and variables associated with the EGFR mutation and its subtypes

1 reference

12 December 2020

The rapidly advancing field of biodefense benefits many other, critical public health concerns

1 reference

12 December 2020

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

12 December 2020

Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development

1 reference

12 December 2020

Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies

1 reference

12 December 2020

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

12 December 2020

Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies

1 reference

12 December 2020

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

1 reference

12 December 2020

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

1 reference

12 December 2020

Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

1 reference

12 December 2020

The IASLC lung cancer staging project. Comparing the current 6(th) TNM edition with the proposed 7(th) edition

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

1 reference

12 December 2020

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

12 December 2020

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

12 December 2020

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

[ERCC1 and RRM1 genes in lung cancer].

1 reference

12 December 2020

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

1 reference

12 December 2020

Global cancer statistics

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

1 reference

12 December 2020

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

12 December 2020

Prognostic factors in non-small cell lung cancer: a decade of progress

1 reference

12 December 2020

Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study.

1 reference

12 December 2020

The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition

1 reference

12 December 2020

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

12 December 2020